AstraZeneca, Targacept initiate depressive disorder drug Phase 2b trial
The study is in addition to the companies’ joint Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD. The RENAISSANCE Program is designed to support
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.